Inhibitors of B cell receptor (BCR) signaling such as the Bruton's tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.